肺腺癌におけるゲフィチニブまたはカルボプラチン–パクリタキセル療法

Mokら（Wed,）はこの課題を研究しました。

www.synapsesocial.com/papers/69da2aa3b48bb130d46849d1 — DOI: https://doi.org/10.1056/nejmoa0810699

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)· 2008 · 203 citations
2. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)· 2005 · 2,088 citations
3. COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER· 2002 · 3,739 citations
4. Resampling-Based Multiple Testing.· 1994 · 913 citations
5. A useful testing strategy in phase iii trials: combined test of superiority and test of equivalence· 1995 · 137 citations